Drug · Small Molecule

Carmustine

CI-DRUG-00000144Explore in graph →NCIt C349 CHEMBL513 CIViC Approved

Regulatory

Approvals (8)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

emaRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
EU EMA	—	Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma).	approved	Jul 18, 2018	ema

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 13 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 3	14	9	36	191	8	CA, EU, US	Dec 31, 1975	1988-04
Non-Hodgkin Lymphoma	Phase3	Phase 3	6	3	8	49	0	—	—	1994-01
Malignant Breast Neoplasm	Phase3	Phase 3	1	1	2	5	0	—	—	1991-12
Malignant Central Nervous System Neoplasm	Phase3	Phase 3	1	1	4	15	0

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MGMT Promoter Methylation1
Carmustine	Glioblastoma

Clinical trials

Trials with this intervention (191)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 101–150 of 191 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01220297	Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT	terminated	Phase 2	3	Stanford UniversityOTHER	1	Jun 5, 2017	clinicaltrials
NCT00477035	Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies	completed	Phase 1

Molecule

Record

Kind: Small Molecule
Mechanism: Glutathione reductase inhibitor; DNA inhibitor; RNA inhibitor
Targets: 1 gene
UNII: U68WG3173Y
Aliases: 1,3-Bis(2-chloroethyl)-1-nitrosourea, 1,3-Bis(beta-chloroethyl)-1-nitrosourea, BCNU, Becenum, Becenun, Bicnu, BiCNU, Bischloroethyl nitrosourea, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Camustine, Carmubris, Carmustin, Carmustina, Carmustine, Carmustine medac, Carmustine medac (previously carmustine obvius), Carmustine obvius, Carmustinum, DTI-015, FDA 0345, FDA-0345, GLIADEL, GLIADEL WAFER, Nitrourean, Nitrumon, N,N'-Bis(2-chloroethyl)-N-nitrosourea, NSC 409962, NSC-409962, NSC409962 … (+6)

Data updated 16 hours agoSource updated unknown

Identifiers

Codes (10)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01AD01	CARMUSTINE
DIN (Health Canada)	00297763